Great Lakes NeuroTechnologies will launch their latest version of their medical device technology used to assess Parkinson’s disease this week at the Movement Disorders Society Congress in Dublin Ireland. According to Joseph P. Giuffrida, PhD, President, the launch of the system in Europe highlights the company’s commitment to expand international marketing and sales.
The device technology called the Kinesia HomeView™ system includes patient-worn motion sensors and a tablet computer to quantitatively assess tremor, bradykinesia, and dyskinesia associated with Parkinson’s disease. Physicians use a web interface to setup patient studies and track symptom responses. Market applications include both in-clinic and home-based telemedicine patient care, programming deep brain stimulation, and providing quantitative endpoints to determine efficacy of clinical trials.
The latest system infrastructure includes several key technology updates to improve the telemedicine experience for Parkinson’s patients, physicians, and researchers. To begin with, the patient take-home kit supports broadband data transfer directly from a patient’s home to a secure server. This allows physicians and researchers immediate online access to real-time symptom reports and video diaries.
Next, miniature, patient-worn motion sensors are instrumented with wireless communications. This minimizes setup time and patient burden during home-based assessments. Finally, physicians and researchers can use their own tablets to view web-based reports. Color-coded mapping provides intuitive quantitative tools to document symptom severity and motor fluctuations.
“As broadband and wireless technologies have matured along with the tablet PC market, our development team has be able to successfully integrate them into the Kinesia platform”, said Greg Ferreri, Software Engineering Manager.
For more information, go to http://www.glneurotech.com/ or call 216-361-5410. To view the Kinesia HomeView, go to http://glneurotech.com/Kinesia-HomeView.
